Drug class
CRISPR/Cas9 gene-edited autologous CD34+ haematopoietic stem-cell therapy
Mechanism of action
Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.
General use cases
- Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
- Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
